10.1021/jm000180n
The research focuses on the investigation of symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as potent inhibitors of leukotriene biosynthesis, with the aim of developing new drug candidates for the treatment of asthma and related inflammatory disorders. The study centers on the compound 4,4-bis(4-(2-quinolylmethoxy)phenyl)pentanoic acid sodium salt (47?Na), which demonstrated high selectivity for inhibiting leukotriene C4 (LTC4) over prostaglandin E2 (PGE2) and showed promising pharmacokinetic properties in rat and cynomolgus monkey models. The experiments involved the synthesis of various bis-QMP analogues, their evaluation in vitro using human neutrophils and in vivo using animal models, and the analysis of their inhibitory activity on leukotriene biosynthesis. The research utilized a range of analytical techniques, including NMR spectroscopy, mass spectrometry, and elemental analysis, to characterize the synthesized compounds and assess their potency, selectivity, and pharmacokinetic properties. The main reactants used in the synthesis included commercially available diphenolic acid, quinolylmethoxyphenyl derivatives, and various reagents for the synthesis and modification of the target compounds. The study concluded that 47?Na (ABT-080) met the design parameters for a drug candidate and has proceeded to phase I human studies for safety and pharmacokinetic evaluation.